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Introduction: Tumor size is a known prognostic factor for early 
stage non–small-cell lung cancer (NSCLC), but its significance in 
node-positive and locally invasive NSCLC has not been extensively 
characterized. We queried the Surveillance, Epidemiology, and End 
Results database to evaluate the prognostic value of tumor size for 
early stage and node-positive and locally invasive NSCLC.
Methods: Patients in Surveillance, Epidemiology, and End Results 
registry with NSCLC diagnosed between 1998 and 2003 were ana-
lyzed. Tumor size was analyzed as a continuous variable. Other 
demographic variables included age, gender, race, histology, primary 
tumor extension, node status, and primary treatment modality (sur-
gery vs. radiation). The Kaplan–Meier method was used to estimate 
overall survival (OS). Cox proportional hazard model was used to 
evaluate whether tumor size was an independent prognostic factor.
Results: In all, 52,287 eligible patients were subgrouped based on 
tumor extension and node status. Tumor size had a significant effect 
on OS in all subgroups defined by tumor extension or node status. 
In addition, tumor size also had statistically significant effect on OS 
in 15 of 16 subgroups defined by tumor extension and nodal status 
after adjustment for other clinical variables. Our model incorporat-
ing tumor size had significantly better predictive accuracy than our 
alternative model without tumor size.
Conclusions: Tumor size is an independent prognostic factor, for 
early stage and node-positive and locally invasive disease. Prediction 
tools, such as nomograms, incorporating more detailed information 
not captured in detail by the routine tumor, node, metastasis classifi-
cation, may improve prediction accuracy of OS in NSCLC.
Key Words: Non–small-cell lung cancer, Tumor size, Survival, SEER.
(J Thorac Oncol. 2015;10: 682–690)
Tumor size is a known prognostic factor for many cancers including non–small-cell lung cancer (NSCLC) with larger 
tumors predicting a worse prognosis in most cases.1 This is 
true especially for node-negative tumors, where tumor size is 
often the main determinant of stage and treatment. In the most 
recent 7th edition of the American Joint Committee on Cancer 
(AJCC) staging system for lung cancer, tumor size is empha-
sized, especially for early stage NSCLC.2–7 In this updated 
classification system, additional size cutoffs were introduced, 
with T1 and T2 tumors divided into subcategories T1a, T1b, 
T2a, and T2b (see Supplemental Table, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A767, size-based 
changes of tumor classification between 6th and 7th tumor, 
node, metastasis [TNM]). In addition, larger (>7 cm) tumors 
were upgraded from T2 in the 6th edition TNM system to 
T3 in the 7th TNM system. Overall staging was changed as 
well. In the prior staging system, any node-negative cancer 
that was greater than 3 cm in diameter was considered stage 
IB (T2N0M0). Now, tumors between 3 and 5 cm (T2a) are 
still considered stage IB, but node-negative tumors between 
5 and 7 cm (T2b) are stage IIA and above 7 cm (T3) are stage 
IIB (see Supplemental Table, Supplemental Digital Content 
2, http://links.lww.com/JTO/A768, changes of staging in 7th 
TNM system due to tumor size changes). These changes in 
staging emphasize the poorer prognosis for patients present-
ing with larger primary tumors.
Although the prognostic significance of tumor size 
for early stage NSCLCs was recognized, its significance in 
node-positive and locally invasive NSCLC has not been as 
well validated. Our hypothesis is that tumor size is useful for 
prognostication even in patients with locally invasive tumors 
or with lymph node involvement. To test this hypothesis, we 
performed an analysis to determine the relationship between 
the tumor size and survival using Surveillance, Epidemiology, 
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and End Results (SEER) database and created an easy-to-use, 
readily applicable nomogram to predict overall survival (OS) 
in routine clinical practice, incorporating tumor size as a con-
tinuous variable.
PATIENTS AND METHODS
This was a retrospective, population-based study using 
cases registered in the SEER database made publicly avail-
able through on-line access. Data were retrieved using the 
Surveillance Research Program, National Cancer Institute 
SEER*Stat software (seer.cancer.gov/seerstat) version 6.3.6. 
Informed consent from the study population was not deemed 
necessary, as the authors had no access to the identities of the 
patients.
Data Collection
The following database was used for selection of cases: 
Incidence—SEER 17 Regs Public-Use, November 2005 Sub 
(1973–2003 varying)—Linked to County Attributes—Total 
US 1969–2003 Counties, National Cancer Institute, Division 
of Cancer Control and Population Sciences (DCCPS), 
Surveillance Research Program, Cancer Statistics Branch, 
released April 2006, based on the November 2005 submission. 
Cases classified as tumors of the lung and bronchus, diagnosed 
between 1998 and 2003, with age 18 to 115 at diagnosis were 
included in the analysis. Only patients with the following his-
tologies (based on International Classification of Diseases for 
Oncology, 3rd edition [ICD-O-3] codes) were included: large 
cell carcinoma, squamous cell carcinoma, adenocarcinoma, 
bronchoalveolar carcinoma, and carcinoma not otherwise 
specified. Cases identified by means of a death certificate only 
or autopsy only were excluded. In addition, cases were required 
to have sufficient information on the size and the extension of 
the primary tumor and involved lymph nodes. Individual data 
for each case were retrieved from the database regarding gen-
der, age at diagnosis, race, tumor size, extension, nodal status, 
the primary treatment modality (surgery and/or radiotherapy), 
survival time, and vital status at last follow-up.
Subgroup Definitions
Primary tumor size in the SEER database is recorded 
according to the following rank order: (1) tumor size from 
the pathology report is used if it is available and when the 
patient has not received radiation or systemic treatment before 
surgery; (2) if the patient receives preoperative systemic ther-
apy (chemotherapy, hormone therapy, and immunotherapy) 
or radiation therapy, the largest tumor size is used, whether 
before or after treatment; and (3) information on tumor size 
from imaging/radiographic techniques is used when there is no 
more specific size information from a pathology or operative 
report. If there is a difference in reported tumor size among 
imaging and radiographic techniques, the largest tumor size 
reported in the record is used.8
Lymph node status is recorded in the following rank 
order: (1) the farthest specific regional lymph node chain 
that is involved either clinically or pathologically is used; 
(2) involved regional lymph nodes from the pathology report 
are used, if it is available, when the patient receives no radi-
ation or systemic treatment before surgery; (3) if there is 
a discrepancy between clinical information and pathologic 
information about the same lymph nodes, the pathologic 
information takes precedence; and (4) if the patient receives 
preoperative systemic therapy (chemotherapy, hormone 
therapy, and immunotherapy) or radiation therapy, the far-
thest involved regional lymph nodes is used, whether this 
is based on information before surgery or after treatment.9 
Based on the nodal status, patients were grouped into N0 
(no lymph node involvement, EOD 10 nodal code 0), N1 
(involvement of ipsilateral intrapulmonary, hilar, or peri-
bronchial nodes, nodal code 1), N2 (involvement of ipsi-
lateral subcarinal, carinal, mediastinal, peri/paratracheal, 
pre/retrotracheal, peri/paraesophageal, aortic, pulmonary 
ligament, or pericardial lymph nodes, nodal code 2), or N3 
(involvement of contralateral hilar or mediastinal lymph 
nodes, supraclavicular lymph nodes, or scalene lymph 
nodes, nodal code 3; Table 1).
Definition of disease extension was based on the SEER 
Extension of Disease coding system (EOD 10). Extension was 
classified as confined to one lung (EOD 10 extension code 
10), involving the mainstem bronchus greater than 2 cm from 
the carina (extension code 20), involving the visceral pleura 
(extension code 40), involving the bronchus less than 2 cm 
from carina (extension code 50), involving the chest wall, 
pericardium, or parietal pleura (extension code 60), extension 
to a rib (extension code 73), or mediastinal extension (exten-
sion code 70). Patients were further grouped into four groups 
based on the extension: E1 (extension code = 10), E2 (exten-
sion codes = 20/40), E3 (extension codes = 50/60/73), and E4 
(extension code = 70; Table 1).
TABLE 1.  Grouping by Tumor Extension and Nodal Involvement (N = Number of Patients)
Node Group
N0 N1 N2 N3
Extension group E1 1 (N = 21,930) 5 (N = 2642) 9 (N = 5410) 13 (N = 694)
E2 2 (N = 6853) 6 (N = 1702) 10 (N = 2873) 14 (N = 295)
E3 3 (N = 2265) 7 (N = 557) 11 (N = 1636) 15 (N = 213)
E4 4 (N = 1340) 8 (N = 409) 12 (N = 3002) 16 (N = 466)
E1, indicates tumor confined to one lung (extension code 10); E2, tumor involving pleura or main stem bronchus ≥ 2 cm from carina (extension codes 20/40); E3, tumor involving 
chest wall or main stem bronchus < 2 cm from carina (extension codes 50/60/73); E4, tumor invading mediastinum (extension code 70); N0, no evidence of regional lymph node 
metastasis; N1, metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes; N2, metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes; N3, metastasis to 
contralateral mediastinal, contralateral hilar, or ipsilateral and/or contralateral supraclavicular or scalene lymph nodes.
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Patients with satellite nodules in the same lobe (EOD 
10 extension code 65) or in a different ipsilateral lobe (EOD 
10 extension code 77), extrapulmonary metastases (extension 
code 85), patients with distant lymph node metastases (nodal 
code 7), and patients with tumor size greater than 40 cm were 
excluded from the analysis. Patients were then divided into 16 
subgroups based on extension and nodal status (Table 1).
Statistical Analysis
The distribution of OS, defined as the time from diagno-
sis of lung cancer to death of any cause, was estimated by the 
Kaplan–Meier method. For each of the 16 subgroups, we ana-
lyzed OS as a function of tumor size. Tumor size was analyzed 
as a continuous variable in the transformation of logarithm to 
the base 2. Other demographic variables included age, gen-
der, race, histology, primary tumor extension, node status, and 
primary treatment modality (surgery vs. radiation vs. both 
vs. neither). Log-rank test was performed to assess for differ-
ences in survival between subgroups. Cox proportional hazard 
model was used to evaluate the effects of multiple variables on 
survival. P values less than 0.05 for main effects and interac-
tion effects were considered statistically significant. All tests 
were two sided.
The predictive accuracy of various Cox regression 
models was quantified by C-index, which provides the area 
under the receiver operating characteristics curve for cen-
sored data.10,11 A C-index of 0.5 indicates that outcomes are 
completely random, whereas a C-index of 1 indicates that 
the model is a perfect predictor. To protect against overfitting 
during stepwise regression, we used a bootstrap procedure as 
implemented in the “validate” function of the Design library,11 
which allows for computation of an unbiased estimate of the 
C-index. We used 100 bootstrap samples. To study whether 
tumor size added predictive information above and beyond 
other important clinical/pathological covariates, we used the 
rcorrp.cens function in the Design library in R to test whether 
the difference in statistical predictive accuracy between Cox 
regression models was significant.10 This function computes 
U-statistics for testing whether the predictions of one model 
are more concordant than those of another model.
Nomogram Development
A nomogram of the final multivariate model was con-
structed as a visualizing aid to obtain predicted values manually 
from a Cox model. Calibration was carried out for the con-
structed nomogram. To adjust for the bias associated with eval-
uating the performance of the nomogram on the same group of 
patients that was used to build the nomogram, the assessment of 
calibration was repeated for 5000 bootstrapped samples.
RESULTS
Patient Characteristics
Based on the patient selection criteria described above, 
52,287 patients with NSCLC were identified from the SEER 
database and analyzed. Among these patients, 49% were 
treated with surgery alone, 24% were treated with radiation 
alone, 10% were treated with surgery and radiation, 15% 
patients did not receive surgery or radiation, and treatment 
was unknown in 3% patients. See Tables 1 and 2 for patient 
characteristics.
Survival Outcomes
On multivariate analysis, younger age, female gender, 
adenocarcinoma histology (vs. squamous or large cell), Asian 
race (vs. white), N0 (vs. N1, N2, or N3), smaller tumors, and 
lower extension subgroups were associated with improved 
OS (Table 2).
Tumor Size Effect on OS
To further determine the prognostic value of primary 
tumor size in patients with NSCLC, we first investigated the 
relationship between OS and tumor size within each of the 
subgroups defined by primary tumor extension (i.e., E1, E2, 
E3, and E4). The multivariable models demonstrated a statisti-
cally significant association between larger size and survival in 
all subgroups, with hazard ratios (95% confidence interval) of 
1.377 (1.34–1.415), 1.37 (1.314–1.429), 1.331 (1.257–1.41), 
and 1.201 (1.145–1.261) for E1, E2, E3, and E4, respectively. 
Figure 1A demonstrates the survival curves according to 
tumor size quartile within each of the E subgroups.
Next, we investigated the relationship between OS and 
the tumor size in patients with N0, N1, N2, and N3 status. The 
multivariable models demonstrated a statistically significant 
association between larger size and survival in all subgroups, 
with hazard ratios (95% confidence interval) of 1.453 (1.413–
1.494), 1.332 (1.251–1.417), 1.219 (1.181–1.258), and 1.191 
(1.093–1.297), for N0, N1, N2, and N3, respectively. Figure 
1B demonstrates the survival curves according to tumor size 
quartile within each of the N subgroups. As expected, the 
association between tumor size and survival is strong and sta-
tistically significant in the group with node-negative tumors. 
Interestingly, this statistically significant association is also 
seen in patients with N1, N2, and N3 disease.
We then analyzed the effect of tumor size on OS using 
multivariate Cox proportional hazards model on each sub-
group defined by tumor extension and nodal involvement 
(Table 1). As shown in Figure 2, tumor size had a statistically 
significant effect on OS in 15 of the 16 subgroups after adjust-
ment for age, sex, race, and histology. The only exception is 
the E4 N3 subgroup.
Risk Models
To further refine the analyses on the prognostic value 
of tumor size, we created two Cox models to predict survival 
incorporating age, sex, race, histology, N stage, and tumor 
extension with and without adding tumor size. The predictive 
ability of the two models was quantified by the C-index, which 
is the area under the receiver operating characteristics curve 
adapted for survival data. The model incorporating tumor 
size has superior predictive accuracy (C-Index = 0.7136) 
compared with the model that incorporated all other factors 
but did not include tumor size (C-Index = 0.7042). Although 
the C-index allows various models to be ranked according to 
accuracy, it cannot be used for hypothesis testing. Therefore, 
we performed a test for concordance to test the hypothesis 
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that the model containing size information outperformed the 
model without size information. The performance improve-
ment of the model incorporating tumor size over the model 
without tumor size was statistically significant by two meth-
ods (p < 0.0001, Table 3).
We then constructed an easy-to-use nomogram based on 
the model with tumor size to increase its clinical usefulness 
(Fig. 3A). Calibration of our nomogram showed that the pre-
dicted 2-year OS was almost identical to the actual observed 
2-year OS with slim estimation bias (Fig. 3B).
DISCUSSION
Here, we present our comprehensive analysis of the 
effect of tumor size on OS of NSCLC patients using the SEER 
database. As expected, in node-negative tumors, there was a 
predictable relationship between tumor size and OS, with 
increasing size correlating with a decrease in survival. A simi-
lar relationship was also observed in locally invasive tumors 
and in tumors with extensive lymph node involvement. In our 
Cox model, tumor size added significant additional predictive 
information for survival beyond all other clinical parameters 
including age, sex, race, histology, N stage, and tumor exten-
sion indicating that tumor size is an independent prognostic 
factor. We developed a nomogram for survival prediction 
including the aforementioned variables, which allows our 
model to be easily applied in clinical practice.
The National Cancer Institute SEER database is the 
only comprehensive source of population-based information 
in the United States that includes stage of cancer at the time of 
diagnosis and patient survival data. The SEER Program cov-
ers approximately 28% of the US population,12 thus encom-
passing a much larger sample size than would otherwise be 
possible with any single institution and most multi-institu-
tional experiences. In addition, SEER provides information 
on patients from across the country in many different treat-
ment settings, both community and academic practices, which 
TABLE 2.  Patient Demographics/Characteristics and Multivariate Analysis for OS
Category
Percentage*  
(N = 52,287)
Multivariate Analysis
Hazard Ratio  
(95% confidence interval) P value
Age (year): median (range) 70 (20–103) 1.032 (1.031–1.034) per year increase
Sex
  Female 46 Reference Reference
  Male 54 1.199 (1.165–1.234) <0.001
Race
  White 85 Reference Reference
  Black 9 1.131 (1.081–1.184) <0.0001
  Asian 5 0.872 (0.817–0.930) <0.0001
  Other/unknown 1 1.004 (0.840–1.201) 0.963
Histology
  Adenocarcinoma 38 Reference Reference
  Bronchoalveolar carcinoma 8 0.569 (0.523–0.618) <0.0001
  Large cell carcinoma 6 1.382 (1.306–1.463) <0.0001
  Squamous cell carcinoma 31 1.224 (1.182–1.268) <0.0001
  NOS 18 1.650 (1.587–1.715) <0.0001
Extension of primary tumor
  E1 59 Reference Reference
  E2 22 1.075 (1.037–1.115) <0.0001
  E3 9 1.506 (1.439–1.575) <0.0001
  E4 10 1.504 (1.440–1.572) <0.0001
N stage
  N0 61 Reference Reference
  N1 10 1.353 (1.290–1.419) <0.0001
  N2 25 2.089 (2.022–2.159) <0.0001
  N3 3 2.548 (2.387–2.720) <0.0001
Primary tumor size (cm)
  Median (range) 3.2 (0.3–38) 1.352 (1.326–1.378) per onefold increase <0.0001
Alive
  Yes 47 NA NA
  No 53 NA NA
*Percentages are rounded and may not add up to 100%.
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FIGURE 1.  The effect of tumor size on OS according to tumor extension groups (A) and N stages (B). Patients in each nodal 
or extension group were separated into four subgroups based on the tumor size ≤2 cm; 2–5 cm; 5–7 cm; and greater than 7 cm. 
OS was analyzed in each subgroup as a function of tumor size.
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makes our analysis more representative of the general US 
patient populations. The robustness of the SEER database 
to identify clinical predictors of outcomes has been recently 
underscored by the revisions to the NSCLC AJCC TNM clas-
sification project undertaken by the International Association 
for the Study of Lung Cancer (IASLC).3,13,14 In this effort, an 
international database was created to identify novel prognostic 
markers in lung cancers, leading to modification of the T clas-
sification and TNM stage grouping.3,14 Importantly, the find-
ings from this prospectively, independently collected database 
were validated using the SEER data, illustrating the accuracy 
of clinical information and survival outcomes collected within 
the context of the SEER program. These observations increase 
the confidence in our results, indicating the importance of 
tumor size in determining survival in patients with early stage 
NSCLC, locally invasive NSCLC, or NSCLC with extensive 
nodal involvement.
Despite the large sample size, one limitation of the 
SEER database, and consequently of our analysis, is the 
lack of information regarding the use of systemic therapy, 
performance status, smoking status, and patterns of failure 
(i.e., development of locoregional and/or distant recurrence). 
Moreover, the optimal definition of adenocarcinoma tumor 
size has recently been readdressed, as appreciated by obser-
vations of possible higher prognostic accuracy conferred by 
determining the size of the invasive components of the tumor, 
measured either pathologically (in invasive tumors with lep-
idic areas) or radiologically (by measuring the solid compo-
nent of part-solid nodules).15 Unfortunately, these data are not 
captured in the SEER database. Nonetheless, even without the 
information on these other prognostic factors and outcome 
parameters, our data strongly suggest that primary tumor size 
should be more comprehensively integrated into the next iter-
ation of the TNM classification/AJCC staging system.
Although tumor size has been recognized previously 
as an important factor for prognosis of patients with NSCLC 
and has been taken into consideration in the TNM Staging 
System,1,6,7 a comprehensive analysis of its impact within the 
subgroups of patients with locally invasive disease and exten-
sive nodal disease has not been performed. For example, early 
efforts evaluating tumor size and survival focused mainly on 
early stage NSCLC, particularly node-negative NSCLC, and 
showed clear evidence that tumor size impacts survival in 
node-negative disease.6,16–28 Other studies included patients 
with node-positive disease, mainly stage II, but the sample 
size was limited, and the proportion of patients with node-
positive diseases was small.29,30 Recent studies have shown 
that tumor size or volume impacts the survival of patients with 
locally advanced NSCLC treated with radiation or chemora-
diotherapy.13,31–33 However, these analyses were again lim-
ited by the small sample size, and treatment modalities were 
restricted to radiation or chemoradiation. Two recent SEER 
FIGURE 2.  Hazard ratio of death per onefold 
increase in tumor size in 16 subgroups based on 
tumor extension and nodal status. The circles rep-
resent the point estimates of hazard ratios of death 
and the bars show the 95% confidence intervals. 
It indicates increased risks of death if hazard ratio 
greater than 1 while decreased risks of death if haz-
ard ratio less than 1. For example, for subgroup 1 
(N0 E1), onefold increase in tumor size is associated 
with 1.456 (1.406–1.508)-fold risks of death.
TABLE 3.  Comparison of Two Cox Models With or Without Incorporating Tumor Size Using the rcorrp.cens Function
Model 1 vs. Model 2 Model 2 vs. Model 1 U-Statistic P Value
Method 1 57.7 42.3 <0.0001
Method 2 4.90 3.96 <0.0001
Model 1: parameters include age, sex, race, histology, nodal stage, tumor extension, and tumor size.
Model 2: parameters include age, sex, race, histology, nodal stage, and tumor extension without tumor size.
Method 1: estimate the fraction of pairs for which the model 1 difference is more impressive than the model 2 difference.
Method 2: estimate the fraction of pairs for which model 1 is concordant with survival data but model 2 is not.
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FIGURE 3. A, Nomogram for predicting OS. Instructions: for each parameter (tumor size, age, gender, race, histology, node 
status, and tumor extension), read the points assigned on a 0 to 100 scale and add these points. Read the results on the ‘Total 
Points’ scale and then read the corresponding predictions below it. Example: an African American 60-year-old male patient with 
an N1, 8 cm adenocarcinoma involving the chest wall, would score a total of 161 points: 9 (black) + 7 (male) + 44 (age) + 21 
(adenocarcinoma) + 15 (extension 60, chest wall invasion) + 11 (N1) + 54 (8 cm size). His predicted 2-year survival rate and 
median survival time would be approximately 35% and approximately 15 months, respectively. Extension codes: 10 (tumor 
confined to one lung), 20/40 (tumor involving pleura or main stem bronchus ≥2 cm from carina), 50/60/73 (tumor involving 
chest wall or main stem bronchus less than 2 cm from carina), and 70 (tumor invading mediastinum). B, Calibration plot for the 
nomogram. The dashed line indicates the ideal reference line where predicted probabilities would match the observed survival 
rates. The dots are calculated from subcohorts of our data and represent the performance of the nomogram based on the Cox 
model. The × marks indicate bootstrap-based, bias-corrected predictions, representing the performance of the nomogram on 
future new data. The closer the solid line is to the dashed line, the more accurate the model predicts OS.
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database-based studies with a larger number of patients have 
attempted to investigate the prognostic significance of tumor 
size in patients with locally advanced NSCLC, and both 
showed tumor size to be an independent prognostic factor.34,35 
However, both studies were focused on stage III disease, while 
node-positive stage IIA and IIB disease were not included. To 
the best of our knowledge, our study is the first comprehensive 
population-based study with the largest sample size includ-
ing node-negative and node-positive NSCLC, evaluating the 
impact of primary tumor size on survival according to both 
nodal involvement and extent/invasiveness of primary tumor.
In previous studies, including the two SEER-based stud-
ies on stage III NSCLCs,34,35 tumor size was subclassified into 
categorical variables, thus potentially resulting in underestima-
tion of the extent of variation in survival among groups and 
concealing nonlinearity in the relation between tumor size and 
survival. In contrast, to best utilize the information on tumor 
size, we looked at tumor size as a continuous variable in the 
multivariate models, potentially improving prediction accuracy.
Our data also corroborate the importance of develop-
ment of other tools that can evaluate multiple variables not 
encompassed by the current staging system, such as the 
nomogram presented herein. We have demonstrated that the 
multivariate model integrating tumor size (as a continuous 
variable), age, gender, race, histology, nodal involvement, and 
primary tumor extension is superior to the AJCC 7th edition 
in predicting OS. We envision that, in the future, collection 
of these and other potential candidate prognostic factors, in 
a more detailed way, using multi-institutional, international, 
large data repositories will allow for the development of more 
accurate methods to predict clinical outcomes, thus assisting 
clinicians in selecting more appropriate therapies tailored to 
each individual patient’s risk. Toward this end, the IASLC has 
expanded their database/staging project to include other vari-
ables, such as performance status, histologic cell type, gender, 
age, and some routine laboratory tests.36 In addition, as bio-
marker analysis become more common in clinical practice, it 
is likely that this information will also contribute to determine 
prognosis. As an example, the presence of epidermal growth 
factor receptor activating mutations in both metastatic37 and 
earlier stage38–40 NSCLC not treated with epidermal growth 
factor receptor inhibitors is associated with improved survival. 
Likewise, we have recently demonstrated that complex intra-
tumor heterogeneity assessed by multiregion whole exome 
sequencing may also be associated with a higher risk of post-
surgical recurrence, and consequently mortality, in localized 
NSCLCs, in a preliminary set of samples.41 We speculate that 
integration of such data to the current prognostic models will 
increase their accuracy, underscoring the importance of creat-
ing nomograms and/or electronic tools that can incorporate 
multiple variables and novel prognostic factors beyond the 
scope of the current AJCC staging system.
In summary, we have demonstrated that larger primary 
tumor size is associated with inferior survival in patients with 
early stage NSCLC, locally advanced disease, and in patients 
with extensive nodal involvement. These data corroborate 
integration of primary tumor size in a more comprehensive 
way into the next iteration of the TNM/AJCC classification 
system. Risk models and nomograms incorporating multiple 
variables, such as primary tumor size (as a continuous vari-
able), age, gender, race, histology, nodal involvement, and 
primary tumor extension, are more accurate in predicting OS 
in nonmetastatic NSCLCs. Our findings may provide a frame-
work to refine prognostication methods for clinical practice, 
as more detailed, large-scale data become available through 
(multi-) national efforts, including information on demo-
graphics, clinical characteristics, and potentially, biomarkers.
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